Batteries used in Implantable cardiac pacemakers-present unique challenges to their developers and manufacturers in terms of high levels of safety and reliability. In addition, the batteries must have longevity to avoid frequent replacements. Technological advances in leads/electrodes have reduced energy requirements by two orders of magnitude. Micro-electronics advances sharply reduce internal current drain concurrently decreasing size and increasing functionality, reliability, and longevity. It is reported that about 600,000 pacemakers are implanted each year worldwide and the total number of people with various types of implanted pacemaker has already crossed 3 million. A cardiac pacemaker uses half of its battery power for cardiac stimulation and the other half for housekeeping tasks such as monitoring and data logging. The first implanted cardiac pacemaker used nickel-cadmium rechargeable battery, later on zinc-mercury battery was developed and used which lasted for over 2 years. Lithium iodine battery invented and used by Wilson Greatbatch and his team in 1972 made the real impact to implantable cardiac pacemakers. This battery lasts for about 10 years and even today is the power source for many manufacturers of cardiac pacemakers. This paper briefly reviews various developments of battery technologies since the inception of cardiac pacemaker and presents the alternative to lithium iodine battery for the near future.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1502062 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Dual-Chamber Leadless Pacemaker Implant Procedure Outcomes: Insights from the AVEIR DR i2i Study.
Heart Rhythm
March 2025
Amsterdam Academic Medical Center, Amsterdam, The Netherlands.
Background: Initial results were recently reported for the AVEIR DR i2i study which involved the percutaneous implantation of a novel dual-chamber leadless pacemaker (LP) system, with right atrial (RA) and ventricular (RV) LPs delivering atrioventricular synchronous pacing.
Objective: Evaluate procedural outcomes and learning curve for de novo implantation of the dual-chamber LP (AVEIR DR™, Abbott).
Methods: Implant procedure metrics collected during the study were analyzed, including procedural complications within 30 days post-implant.
Case Report: Dual-chamber pacemaker for hypertrophic cardiomyopathy with bradyarrhythmia and idiopathic pericardial effusion: a report of two cases and literature review.
Front Cardiovasc Med
February 2025
Department of Cardiology, Shandong Provincial Medical and Health Laboratory of Cardiac Electrophysiology and Arrhythmia, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China.
Background: Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disorder characterized by asymmetric hypertrophy of the ventricles and the ventricular septum, leading to subsequent left ventricular outflow tract (LVOT) obstruction and diastolic dysfunction. Typically, patients with HCM experience sinus tachycardia and sinus arrest relatively infrequently. In addition, the concurrent occurrence of HCM with non-surgically induced (ablation or myectomy) bradyarrhythmia and idiopathic pericardial effusion in adult patients has not been previously reported.
View Article and Find Full Text PDFClinical results of combined aortic valve-sparing root replacement and mitral valve repair.
Interdiscip Cardiovasc Thorac Surg
March 2025
Department of Cardiovascular & Thoracic Surgery, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
Objectives: Aortic valve-sparing root replacement using the reimplantation technique and mitral valve repair are well-established surgical approaches for the treatment of aortic root pathologies and mitral valve insufficiency. However, the management of concomitant diseases with a dual valve-preserving strategy remains poorly described. Therefore, the aim of this study is to evaluate the long-term outcomes of concomitant valve sparing surgery and mitral valve repair.
View Article and Find Full Text PDFTissue elasticity modulates cardiac pacemaker cell automaticity.
Am J Physiol Heart Circ Physiol
March 2025
Blalock-Taussig-Thomas Pediatric and Congenital Heart Center, Johns Hopkins Children's Center.
Tissue elasticity is essential to a broad spectrum of cell biology and organ function including the heart. Routine cell culture models on rigid polystyrene dishes are limited in studying the impact of tissue elasticity in distinct regions of the myocardium such as the cardiac conduction system. Gelatin, a derivative of collagen, is a simple and tunable platform for modeling tissue elasticity.
View Article and Find Full Text PDFUnveiling the Reason for Syncope Associated With Cardiac Nodules.
Pacing Clin Electrophysiol
March 2025
Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Behcet's disease is a systemic immune-mediated vasculitis predominantly affecting males. Cardiac involvement, termed cardiac Behcet's disease, is rare but potentially fatal, often mimicking infective endocarditis. This case presented with syncope as the initial symptom, leading to the identification of a non-coronary aortic sinus nodule, suspected as the cause of intermittent complete atrioventricular block.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!